Possible Buying Opportunities? Hecla Mining Corp (HL), Inuvo Inc (INUV) and Actinium Pharmaceuticals Inc (ATNM)

Posted by admin April 7, 2015 0 Comment 1231 views

New York, NY – GDP INSIDER  –  04/07/2015.

This article discusses three companies: Hecla Mining Corp (NYSE:HL), Inuvo Inc (NYSEMKT:INUV) and Actinium Pharmaceuticals Inc (NYSEMKT:ATNM)

Hecla Mining Corp (NYSE:HL) continued to add to its recent gains yesterday with the stock climbing another 3.77% or $0.12 to close at $3.30, on fairly sedate trading of 4.187 million shares, compared to its three month average trading volume of 6.536 million. The precious metal company focused on producing and marketing gold, silver and zinc has been enjoying the benefits of other commodities woes, as investors flock to stocks that are traditionally safe. Having just passed a bullish MACD crossover, Hecla Mining Corp still has further growth potential making it a strong hold.

Should You Invest In Hecla Mining Corp? Read Our Free HL Analysis To Know More.

Inuvo Inc (NYSEMKT:INUV) posted very strong gains yesterday with the stock skyrocketing 28.80% to finish the day at a closing price of $2.46 on heavy trading of 1.689 million, compared to its three month average trading volume of 0.166 million. Inuvo Inc’s drastic increase in value came despite the fact that the company did not make any significant announcement or release any financial figures. The stock has gained 241.67% over the past one year, far outstripping the performance of S&P 500 which has only gained 12.77% over the same period. In addition, the RSI and MFI are 78.18 and 78.82, respectively. Both of these indicate the bullish move could continue, and the technical are not indicating any near-term reversal.

Where Is Inuvo Inc Heading? Buying Into INUV Now Could Help Your Portfolio. Click Here To See How.

Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) saw an increase of 9.38% or $0.24 to finish the day at a closing price of $2.80 on higher than average trading volume of 1.01 million shares, compared to its 30 day average trading volume of 0.377 million. The US-based biopharmaceutical company developing cancer drugs is currently situated 81.33% below its 52 week high of $15. Over the past one month and over the past one quarter, the shares of Actinium Pharmaceuticals Inc have lost 7.89% and 52.22%, respectively. However, with RSI of 44.60 and one year target price estimate of $16, the stock has plenty of upside potential, hold.

Can Actinium Pharmaceuticals Inc Rebound From Its Disappointing Losses? Click Here To See If It’s Time To Buy ATNM Or Stay On The Sideline.

About UltimateStockAlerts

UltimateStockAlerts.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.

Write Your Comment